University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Hideho Okada, MD, PhD

Hideho Okada, MD, PhD

Professor of Neurological Surgery, Surgery and Immunology, UCSF

Cancer Center Program Memberships

Neurologic Oncology | Cancer Immunology

Research Summary

As a physician scientist, I have been dedicated to brain tumor immunology and development of effective immunotherapy for brain tumors for over 20 years. My team was one of very first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific neoantigens, and found critical roles for the integrin receptor known as very late activation antigen (VLA)-4 in facilitating entry of CTLs to the brain tumor site. I have translated these discoveries into novel vaccine and immune-gene therapy clinical studies in both adult and pediatric brain tumor patients. I am a member in the American Society for Clinical Investigation (2010-present), an honored society for physicians who promote laboratory science to the clinic. My current national and international leadership roles include: chair of the immunotherapy subgroup at the NCI-sponsored Adult Brain Tumor Consortium; a Steering Committee member of the Cancer Immunology Working Group in the American Association for Cancer Research (AACR); a co-chair for Education Day at 2015 the Society for Neuro-Oncology annual meeting; and an Organizing Committee member for the 2015 Annual Meeting of the AACR.

Education

Nagoya University School of Medicine-Japan, M.D., 1991, Medicine
Nagoya University School of Medicine-Japan, Ph.D., 1996, Medicine
Handa Municipal Hospital-Japan, Internship, Residency, 1991-1992
Nagoya University School of Medicine-Japan, Residency, 1992-1996, Neurosurgery


Professional Experience

  • 1998-2001
    Research Assistant Professor, Department of Neurosurgery, UPSOM 
  • 2001-2006
    Assistant Professor, Department of Neurosurgery and Surgery, UPSOM
  • 2004-present
    Co-Program Leader, Brain Tumor Program, University of Pittsburgh Cancer Institute
  • 2007-2012
    Associate Professor, Department of Neurosurgery and Surgery, UPSOM
  • 2012-present
    Professor, Department of Neurosurgery, Surgery and Immunology UPSOM

Honors & Awards

  • 1996
    Uehara Memorial Foundation Postdoctoral Scholarship
  • 1998
    First Place, Award for Scientific Excellence and Potential, 10th Annual University of Pittsburgh, Cancer Institute Scientific Retreat
  • 2001
    Doris Duke Charitable Foundation’s Clinical Scientist Development Award
  • 2003
    James S. McDonnell Foundation 21st Century Science Initiative Research Award: Brain Cancer Research
  • 2007
    Excellence in Translational Medicine Award 2006-07 from Journal of Translational Medicine
  • 2008
    University of Pittsburgh Innovator Award
  • 2010
    Team Science Recognition Award by Society for Immunotherapy of Cancer
  • 2011
    Faculty Honoree in the Annual Convocation of University of Pittsburgh

Selected Publications

  1. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 Jul 19; 9(399).
    View on PubMed
  2. Okada H, Thorne SH. Is the immune response a friend or foe for viral therapy of glioma? Neuro Oncol. 2017 Jul 01; 19(7):882-883.
    View on PubMed
  3. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017 Apr 03; 127(4):1425-1437.
    View on PubMed
  4. Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017 Jun 29; 36(26):3749-3759.
    View on PubMed
  5. Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A. Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am. 2017 Feb; 27(1):155-166.
    View on PubMed
  6. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016 Dec; 130(3):517-527.
    View on PubMed
  7. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 Dec; 130(3):543-552.
    View on PubMed
  8. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 Aug 10; 6:31397.
    View on PubMed
  9. Lin Y, Okada H. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016 Oct; 16(10):1265-75.
    View on PubMed
  10. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016 Oct; 18(10):1402-12.
    View on PubMed
  11. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016 Aug; 18(8):1157-68.
    View on PubMed
  12. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332.
    View on PubMed
  13. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015 Dec; 125(3):631-5.
    View on PubMed
  14. Dunn GP, Okada H. Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii3-vii8.
    View on PubMed
  15. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-42.
    View on PubMed
  16. Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology. 2015 Nov; 4(11):e1047581.
    View on PubMed
  17. Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015 Jun; 4(6):e1008347.
    View on PubMed
  18. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46.
    View on PubMed
  19. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22.
    View on PubMed
  20. Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun. 2015 Mar 13; 458(3):549-54.
    View on PubMed

Go to UCSF Profiles, powered by CTSI